Genetically engineered chickens were needed to produce Kanuma (sebelipase alfa), newly approved by FDA to treat lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease in which patients suffer multi-organ damage and premature death.
Here are the top 3 value-based healthcare developments of 2015 and the top 3 ways to advance value-based care in 2016.
Pharmacists in California and Oregon will soon be able to prescribe birth control.
Information sharing, coordination are key to realizing the genomic revolution in medicine.
Price, comorbidities are as important as TKI choice for patients with chronic myeloid leukemia
Scientists explore innovative delivery systems that might one day treat hemophilia and other blood diseases
Researchers see promising early clinical trials with checkpoint-inhibitor therapies, opening the door for checkpoint-blockade combo therapies.
The Pulmonary Fibrosis Foundation and Boehringer Ingelheim’s new five-year partnership, aims to raise awareness of pulmonary fibrosis, provide disease education and advance care and funding research for the PF community
As researchers uncover biomarkers for cancer subtypes, collaboration between researchers, pathologists and physicians will improve accurate diagnosis of lymphoma subtypes.
Next-generation gene sequencing and other advanced technologies for personalized medicine may soon identify biomarkers that will improve treatment response and long-term toxicity risks for childhood cancer patients.
AML’s genetic complexity raises concerns about long-term prospects of single mutation-targeting agents
Myeloma combination treatments get the once-over by leading cancer expert.
A new US Congressional report about the price of hepatitis C drug Sovaldi, along with a new class action lawsuit against Blue Cross Blue Shield involving Harvoni coverage, are the latest in a series of controversies surrounding the 2 drugs.
As technology has evolved, the potential of population health management as a tool to improve quality and reduce costs has expanded.
In today’s world of value-based care, having a high volume of inpatients means something is broken in the healthcare system. Here's how technology is helping fix it.
FDA has approved elotuzumab (Empliciti, Bristol-Myers Squibb and AbbVie) for the treatment of multiple myeloma.
Greg Scott, national leader of the health plans practice at Deloitte Consulting, LLP, shares how plans and providers may be able to better apply big data.
As 2015 comes to a close, a look at this year's challenges and next year's opportunities.
In this Q&A, a presenter at the upcoming ASH conference discusses new hematology payment models and the top challenges payers face in this area.
Express Scripts is partnering with Imprimis Pharmaceuticals to provide access to a low-cost alternative to Daraprim (pyrimethamine). Here's why.
A study published in the October 26th issue of the JAMA Internal Medicine journal shows that physicians don't typically reduce older patients' diabetic medications, even when the patients have low blood sugar levels.
A new joint program with the Mount Sinai Health System and Livongo Health, a consumer digital health company, is expected to help diabetics manage their disease better.
In its latest round of cancer drug approvals, the FDA last week approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC).
Managed Healthcare Executive's State of the Industry Survey findings reveal that most plans and providers are struggling with data analytics. Here are some tips.
As a physician, I’ve repeatedly wondered over the years when a variation of remote monitoring technology would advance to help patients. Finally, it seems that time is here.
The top 5 industry challenges facing managed care executives, according to the findings of Managed Healthcare Executive's State of the Industry Survey.
Experts say you should follow these 6 therapeutic areas.
The results of a large study of the impact of empagliflozin (Jardiance) on cardiovascular outcomes were recently published. Here are some key takeaways.
Insurers like Aetna are implementing payment models for hematologic conditions.
